148 related articles for article (PubMed ID: 30187994)
1. Synergistic antimetastatic effect of cotreatment with licochalcone A and sorafenib on human hepatocellular carcinoma cells through the inactivation of MKK4/JNK and uPA expression.
Wu MH; Chiu YF; Wu WJ; Wu PL; Lin CY; Lin CL; Hsieh YH; Liu CJ
Environ Toxicol; 2018 Dec; 33(12):1237-1244. PubMed ID: 30187994
[TBL] [Abstract][Full Text] [Related]
2. Licochalcone A suppresses migration and invasion of human hepatocellular carcinoma cells through downregulation of MKK4/JNK via NF-κB mediated urokinase plasminogen activator expression.
Tsai JP; Hsiao PC; Yang SF; Hsieh SC; Bau DT; Ling CL; Pai CL; Hsieh YH
PLoS One; 2014; 9(1):e86537. PubMed ID: 24466137
[TBL] [Abstract][Full Text] [Related]
3. Emodin Sensitizes Hepatocellular Carcinoma Cells to the Anti-Cancer Effect of Sorafenib through Suppression of Cholesterol Metabolism.
Kim YS; Lee YM; Oh TI; Shin DH; Kim GH; Kan SY; Kang H; Kim JH; Kim BM; Yim WJ; Lim JH
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30321984
[TBL] [Abstract][Full Text] [Related]
4. Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression.
Hsieh SC; Tsai JP; Yang SF; Tang MJ; Hsieh YH
Amino Acids; 2014 Dec; 46(12):2809-22. PubMed ID: 25245054
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.
Zhai JM; Yin XY; Lai YR; Hou X; Cai JP; Hao XY; Liang LJ; Zhang LJ
Cancer Chemother Pharmacol; 2013 May; 71(5):1255-64. PubMed ID: 23435877
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
[TBL] [Abstract][Full Text] [Related]
7. A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma.
Hu B; Sun D; Sun C; Sun YF; Sun HX; Zhu QF; Yang XR; Gao YB; Tang WG; Fan J; Maitra A; Anders RA; Xu Y
Biochem Biophys Res Commun; 2015 Dec; 468(4):525-32. PubMed ID: 26482853
[TBL] [Abstract][Full Text] [Related]
8. Capsaicin and sorafenib combination treatment exerts synergistic anti‑hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.
Dai N; Ye R; He Q; Guo P; Chen H; Zhang Q
Oncol Rep; 2018 Dec; 40(6):3235-3248. PubMed ID: 30272354
[TBL] [Abstract][Full Text] [Related]
9. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
Chen KF; Yu HC; Liu TH; Lee SS; Chen PJ; Cheng AL
J Hepatol; 2010 Jan; 52(1):88-95. PubMed ID: 19913321
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of the microtubule inhibitor MBRI-001 against human hepatocellular carcinoma as monotherapy or in combination with sorafenib.
Deng M; Li L; Zhao J; Yuan S; Li W
Cancer Chemother Pharmacol; 2018 May; 81(5):853-862. PubMed ID: 29532153
[TBL] [Abstract][Full Text] [Related]
11. Knockout of ADAM10 enhances sorafenib antitumor activity of hepatocellular carcinoma in vitro and in vivo.
Zhang W; Liu S; Liu K; Ji B; Wang Y; Liu Y
Oncol Rep; 2014 Nov; 32(5):1913-22. PubMed ID: 25176394
[TBL] [Abstract][Full Text] [Related]
12. Meloxicam combined with sorafenib synergistically inhibits tumor growth of human hepatocellular carcinoma cells via ER stress-related apoptosis.
Zhong J; Xiu P; Dong X; Wang F; Wei H; Wang X; Xu Z; Liu F; Li T; Wang Y; Li J
Oncol Rep; 2015 Oct; 34(4):2142-50. PubMed ID: 26252057
[TBL] [Abstract][Full Text] [Related]
13. Ropivacaine combined with sorafenib attenuates hepatocellular carcinoma cell proliferation and metastasis by inhibiting the miR-224/HOXD10 axis.
Wang W; Wang T; Lin H; Liu D; Yu P; Zhang J
Environ Toxicol; 2024 Apr; 39(4):2429-2438. PubMed ID: 38197552
[TBL] [Abstract][Full Text] [Related]
14. Melatonin promotes sorafenib-induced apoptosis through synergistic activation of JNK/c-jun pathway in human hepatocellular carcinoma.
Lin S; Hoffmann K; Gao C; Petrulionis M; Herr I; Schemmer P
J Pineal Res; 2017 Apr; 62(3):. PubMed ID: 28178378
[TBL] [Abstract][Full Text] [Related]
15. Butein inhibits the migration and invasion of SK-HEP-1 human hepatocarcinoma cells through suppressing the ERK, JNK, p38, and uPA signaling multiple pathways.
Ma CY; Ji WT; Chueh FS; Yang JS; Chen PY; Yu CC; Chung JG
J Agric Food Chem; 2011 Aug; 59(16):9032-8. PubMed ID: 21770460
[TBL] [Abstract][Full Text] [Related]
16. LicA induces autophagy through ULK1/Atg13 and ROS pathway in human hepatocellular carcinoma cells.
Niu Q; Zhao W; Wang J; Li C; Yan T; Lv W; Wang G; Duan W; Zhang T; Wang K; Zhou D
Int J Mol Med; 2018 May; 41(5):2601-2608. PubMed ID: 29484365
[TBL] [Abstract][Full Text] [Related]
17. Urokinase-type Plasminogen Activator Is a Therapeutic Target for Overcoming Sorafenib Resistance in Hepatoma Cells.
Osawa M; Matsuda Y; Kinoshita Y; Wakai T
Anticancer Res; 2021 Feb; 41(2):645-660. PubMed ID: 33517269
[TBL] [Abstract][Full Text] [Related]
18. Up-Regulation of PAI-1 and Down-Regulation of uPA Are Involved in Suppression of Invasiveness and Motility of Hepatocellular Carcinoma Cells by a Natural Compound Berberine.
Wang X; Wang N; Li H; Liu M; Cao F; Yu X; Zhang J; Tan Y; Xiang L; Feng Y
Int J Mol Sci; 2016 Apr; 17(4):577. PubMed ID: 27092498
[TBL] [Abstract][Full Text] [Related]
19. Low-density lipoprotein decorated silica nanoparticles co-delivering sorafenib and doxorubicin for effective treatment of hepatocellular carcinoma.
Ye J; Zhang R; Chai W; Du X
Drug Deliv; 2018 Nov; 25(1):2007-2014. PubMed ID: 30799656
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1.
Wei JC; Meng FD; Qu K; Wang ZX; Wu QF; Zhang LQ; Pang Q; Liu C
Acta Pharmacol Sin; 2015 Feb; 36(2):241-51. PubMed ID: 25557114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
